 |
|
Molecules might identify high-risk acute-leukemia patients
January 16, 2008COLUMBUS, Ohio - New research suggests that certain small molecules used by cells to control the proteins they make might also help doctors identify adult acute-leukemia patients who are likely to respond poorly to therapy.
Researchers say the findings should improve the understanding of acute myeloid leukemia (AML) and could lead to new therapies for patients with few treatment options.
The study examined the levels of molecules called microRNAs in leukemia cells from 122 patients with high- and intermediate-risk AML and in normal blood stem cells from 10 healthy donors.
The findings showed that both the leukemia cells and their normal counterparts had similar kinds of microRNA, but that the two groups differed in the levels of miRNAs present.
The research also identified two microRNAs present at abnormally high levels that were clearly associated with patient survival.
The investigators verified their findings in an additional group of 60 patients using a different technology.
The study, published online Jan. 10 in the journal Blood, was led by researchers with The Ohio State University Comprehensive Cancer Center and the M.D. Anderson Cancer Center.
"If our results are validated by other groups, these two elevated microRNAs can be used to determine which patients require more aggressive treatment," says first author Dr. Ramiro Garzon, assistant professor of internal medicine and a researcher with The Ohio State University Comprehensive Cancer Center.
"In addition, they may provide new targets for future therapies - knocking out these two microRNAs might benefit patients who have a poor prognosis."
This possibility is particularly intriguing, he says, because the two microRNAs - called miR-191 and miR-199a - are also associated with cancers of the lung, prostate, colon, stomach and breast. This suggests that they may be part of a common cancer pathway.
Garzon noted that the study also found an association between high levels of a microRNA called miR-155 in AML patients and a gene mutation called FLT3-ITD. High levels of this microRNA have been reported in other cancers and to cause leukemia in mice.
"Clearly, our findings suggest that the quantity of microRNAs present is important in cancer, suggesting that modulating their levels might offer an effective way to treat the disease in these patients," he says.
For this study, Garzon and his colleagues used blood samples from newly diagnosed AML patients who had either normal-looking chromosomes, a feature that indicates intermediate risk of recurrence, or other chromosome alterations. These included isolated trisomy 8, the t(11q23) translocation and multiple chromosomal abnormalities that signal a high risk of recurrence.
Together, these groups make up the majority of the 13,400 people expected to be diagnosed with AML in 2007. About 9,000 people that year were expected to die of the disease.
"Our efforts now should concentrate on characterizing how these altered microRNAs might promote leukemia and on developing drugs designed to inhibit their action," Garzon says.
Ohio State University Medical Center
The findings showed that both the leukemia cells and their normal counterparts had similar kinds of microRNA, but that the two groups differed in the levels of miRNAs present.
The research also identified two microRNAs present at abnormally high levels that were clearly associated with patient survival.
The investigators verified their findings in an additional group of 60 patients using a different technology.
The study, published online Jan. 10 in the journal Blood, was led by researchers with The Ohio State University Comprehensive Cancer Center and the M.D. Anderson Cancer Center.
"If our results are validated by other groups, these two elevated microRNAs can be used to determine which patients require more aggressive treatment," says first author Dr. Ramiro Garzon, assistant professor of internal medicine and a researcher with The Ohio State University Comprehensive Cancer Center.
"In addition, they may provide new targets for future therapies - knocking out these two microRNAs might benefit patients who have a poor prognosis."
This possibility is particularly intriguing, he says, because the two microRNAs - called miR-191 and miR-199a - are also associated with cancers of the lung, prostate, colon, stomach and breast. This suggests that they may be part of a common cancer pathway.
Garzon noted that the study also found an association between high levels of a microRNA called miR-155 in AML patients and a gene mutation called FLT3-ITD. High levels of this microRNA have been reported in other cancers and to cause leukemia in mice.
"Clearly, our findings suggest that the quantity of microRNAs present is important in cancer, suggesting that modulating their levels might offer an effective way to treat the disease in these patients," he says.
For this study, Garzon and his colleagues used blood samples from newly diagnosed AML patients who had either normal-looking chromosomes, a feature that indicates intermediate risk of recurrence, or other chromosome alterations. These included isolated trisomy 8, the t(11q23) translocation and multiple chromosomal abnormalities that signal a high risk of recurrence.
Together, these groups make up the majority of the 13,400 people expected to be diagnosed with AML in 2007. About 9,000 people that year were expected to die of the disease.
"Our efforts now should concentrate on characterizing how these altered microRNAs might promote leukemia and on developing drugs designed to inhibit their action," Garzon says.
Ohio State University Medical Center
Leukemia Current Events and Leukemia News RSSFDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
First use of antibody and stem cell transplantation to successfully treat advanced leukemia
For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.
American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding
The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.
Drug shows promise in treating dangerous complication of erectile disorder
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston.
Brain tumors in childhood leave a lasting mark on cognition, life status
Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.
Researchers use drug-radiation combo to eradicate lung cancer
Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.
Propolis has proved to be a product with ability to have beneficial effects for health
Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses.
Chemosensitivity of cancer cells depends on their protein dependency
Two different anti-apoptotic proteins support cancer cell survival via an identical mechanism, yet differ in their sensitivity to chemotherapeutic drugs, report Brunelle et al. The study will be published online October 26, 2009 and in the November 2, 2009 print issue of the Journal of Cell Biology (JCB).
Drug could provide first treatment for scleroderma
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive.
New chromosomal abnormality identified in leukemia associated with Down syndrome
Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.
More Leukemia Current Events and Leukemia News Articles
 |
100 Q&A About Leukemia, Second Edition (100 Questions & Answers about) by Edward D. Ball (Author) This book deals with leukemia from a doctor's and a patient's perspective. |
 |
Childhood Leukemia: A Guide for Families, Friends and Caregivers (3rd Edition) by Nancy Keene (Author) This most complete parent guide available covers not only detailed and precise medical information about leukemia and the various treatment options, but also day-to-day practical advice on how to cope with procedures, hospitalization, family and friends, school, social and financial issues, communication, feelings, and, if therapy is not successful, the difficult issues of death and bereavement. Woven among the medical details and the practical advice are the voices of parents and children who have lived with leukemia and its treatments. As many parents have already found, advice from "veteran" parents can be a lifeline.This third edition contains significant updates to the information on treatments, chemotherapy drugs, bone marrow transplants, coping with side effects, and resources. It... |
 |
Leukemia (The Biology of Cancer) by Donna M. Bozzone (Author) This book includes full-color photographs, glossary, sidebars, further reading, web sites, references, and an index. Leukemia, or cancer of the blood or bone marrow, occurs in both acute and chronic forms. While the exact causes of the disease are not known, several risk factors have been identified. There are four major types of leukemia: acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), and chronic lymphoid leukemia (CLL), and treatments include chemotherapy, radiation, and bone marrow transplants. "Leukemia" discusses the science of leukemia, theories about its causes, the history of the disease, and the current treatments and how they work. |
 |
Fight Against Acute Lymphoblastic Leukemia Long Sleeve T-shirt Large White by Shop Zeus |
 |
Understanding MDS/Leukemia Part of the award winning public television series Healthy Body/Healthy Mind. It can begin as a harmless case of fatigue but can lead to a blood transfusion or possible bone marrow transplant. It's a disease virtually unknown to the general public and often not diagnosed by medical caregivers. Mylodysplastic syndrome, or MDS, is a disorder of the bone marrow and can lead to leukemia and eventually death. In this program, success stories abound as researchers struggle to find answers. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Living Through Leukemia: A Journey to Health by Louis George Whitehead (Author) While many believe that being diagnosed with leukemia is like being handed a death sentence, South Dakota native Louis George Whitehead provides living proof that survival of this life-threatening and life-changing illness is possible. At age twenty-one, Whitehead’s doctor informs him that he is suffering from acute myeloid leukemia. After two rounds of chemotherapy and a relapse a few months later, Whitehead makes the decision to undergo a bone-marrow transplant. Living through Leukemia chronicles his story of endurance and optimism. Whitehead shares his feelings following his initial diagnosis and through the realization that a fatal outcome was possible. He also details the events and symptoms leading up to his courageous battle and describes the importance of both his... |
 |
When Cancer Calls … Say Yes to Life: The Story of One Man’s Journey through Leukemia by Rusty Hammer (Author) “Rusty Hammer is an inspiration … We have watched his battle with admiration, for it is a tribute to the human spirit, and to the dignity and courage of a good man.” —Mayor Antonio Villaraigosa， City of Los Angeles Shortly after his fiftieth birthday in 2003, Rusty Hammer’s life irrevocably changed. Diagnosed with a rare and aggressive form of leukemia, he had two choices: fight or give in. And he chose to fight. When Cancer Calls … Say Yes to Life shares Rusty Hammer’s courageous journey through cancer. With rare candor, Hammer describes how he faced his future with hope instead of succumbing to the blackness of despair. Hammer illustrates how imperative it is to live our lives to the fullest for our own emotional and physical well-being. ... |
 |
Leukemia Awareness Green Genuine Swarovski Crystal Bracelet by SilverSpeck.com This Beautiful Green Genuine Swarovski Crystal Bracelet Is the Perfect Bracelet you have been waiting for. It has a Sparking Glimmer and is beaded on a Comfort Stretch band. Looks great when worn with a few at a time or alone. Crystal beads can also be used to create your own jewelry! Very Stylish and Pretty! |
 |
Assure FeLv Feline Leukemia Virus Antigen Test Kit 25 tests by Synbiotics Corporation A non-invasive saliva test accurate enough for general FeLv testing, pre-vaccination & health screens. Ideal for detection of viral shedding or to confirm blood ELISA positives. This versatile diagnostic tool utilizes saliva, whole blood, plasma or serum. Pre-measured reagents plus your sample. Must be refrigerated until ready to use. Warm to room temp before using. |
 |
Chemo to the Rescue: A Children's Book About Leukemia by Mary Brent (Author), Caitlin Knutsson (Contributor) When my daughter, Caitlin, was diagnosed with leukemia, she was five years old. Our life changed dramatically, and it was hard to answer the questions she had about her illness and explain why she must go through chemotherapy for such a long time. At one point she began to rebel against the treatment, not understanding that the medicine that was making her feel bad was actually saving her life. Creating this book with Caitlin helped her to come to terms with her illness and accept the treatment. It gave her the power she needed to fight and be strong during the difficult times. She is now eight years old and fully recovered. She looks back on this time as challenging, yet with pride. We hope that our book will encourage other children in the same way by providing a positive outlook to... |
| © 2009 BrightSurf.com |